Amendment to Specification:

Please amend the specification as follows:

Please replace the second row of the table at **page 506** (referring to compound 7.4.176) with the following rewritten paragraphs:

7.4.176	N4-[3-(N-2- Aminoethylamino)carbonyl-3 4- trifluoromethoxyphenyl]-5-fluoro- N2-[3-(N- methylamino)carbonylmethyleneoxyp henyl]-2,4-pyrimidinediamine	A solution of N4-(3-carboxy-4-trifluoromethoxyphenyl)-5-fluoro-N2-[3-(N-methylamino)carbonylmethyleneoxyphenyl]-2,4-pyrimidinediamine in DMF was treated with PyBroP and 1,2-diaminoethane. The mixture was stirred for 1 hour at 22 °C and purified by flash chromatography on silica gel to give N4-[3-(N-2-aminoethylamino)carbonyl-3-
	(R950406)	trifluoromethoxyphenyl]-5-fluoro-N2-[3-(N-methylamino)carbonylmethyleneoxyphenyl]-2,4-pyrimidinediamine as a white solid. LCMS: purity: 100%; MS (m/e): 538.5 (MH ⁺).

Please replace the last two rows of the table at **page 582** (referring to compounds 7.4.416 and 7.4.417) with the following rewritten paragraphs:

7.4.416	N4-(2,2-Dimethyl-3-oxo-4H-benz[1,4]oxazin-6-yl)-5-fluoro-N4 N2-(indazolin-6-yl)-2,4- pyrimidinediamine Benzenesulfonic Acid Salt (R935429)	N4-(2,2-dimethyl-3-oxo-4H-benz[1,4]oxazine-6-yl)-5-fluoro-N4 N2-(indazolin-6-yl)-2,4-pyrimidinediamine (1.5 g, 3.57 mmol) in MeOH (20 mL) was cooled to 0 °C. To the above contents, benzenesulfonic acid (0.594 g, 3.75 mmol, 98%) dissolved in CH ₃ CN (20 ml) was added dropwise for 5 min. The clear solution formed was stirred (15 min) at the same temperature and allowed to warm to room temperature (60 min). The clear solution turned into precipitated form. The reaction mixture was concentrated, dissolved in MeOH (4 mL) and triturated with EtOAC:n-hexanes. The solid obtained was filtered and dried under high vacuum to provide N4-(2,2-dimethyl-3-oxo-4H-benz[1,4]oxazin-6-yl)-5-fluoro-N4 N2-(indazolin-6-yl)-2,4-pyrimidinediamine Benzenesulfonic Acid Salt. ¹H NMR (DMSO-d6): 8 10.70 (s, 1H), 10.34 (s, 1H), 9.99 (s, 1H), 8.21 (d, 1H, J= 5.3 Hz), 8.00 (d, 1H, J= 1.8 Hz), 7.67 (d, 2H, J= 8.5 Hz), 7.60-7.57 (m, 2H), 7.34-7.28 (m, 4H), 7.19 (dd, 1H, J= 8.8 and 1.8 Hz), 7.10 (d, 1H, J= 2.3 Hz), 6.87 (d, 1H, J= 8.0 Hz), 1.36 (s, 6H), J CMS: ret_time: 8.39 min
		7.19 (dd, 1H, J= 8.8 and 1.8 Hz), 7.10 (d, 1H, J= 2.3 Hz), 6.87 (d, 1H, J= 8.0 Hz), 1.36 (s, 6H). LCMS: ret. time: 8.39 min.; purity: 100%; MS (m/e): 420 (MH ⁺).

7.4.417	N4-(2,2-Dimethyl-3-oxo-4H-	In like manner to the preparation of N4-(2,2-dimethyl-3-oxo-
	benz[1,4]oxazin-6-yl)-5-fluoro-N4	4H-benz[1,4]oxazin-6-yl)-5-fluoro-N4 N2-(indazolin-6-yl)-
	N2-(indazolin-6-yl)-2,4-	2,4-pyrimidinediamine benzenesulfonic acid salt, N4-(2,2-
	pyrimidinediamine <i>p</i> -	dimethyl-3-oxo-4H-benz[1,4]oxazin-6-yl)-5-fluoro-N4 N2-
	Toluenesulfonic Acid Salt	(indazolin-6-yl)-2,4-pyrimidinediamine was reacted with p-
	(R935430)	toluenesulfonic acid monohydrate to give N4-(2,2-dimethyl-3-
		oxo-4H-benz[1,4]oxazin-6-yl)-5-fluoro-N4 N2-(indazolin-6-
		yl)-2,4-pyrimidinediamine <i>p</i> -toluenesulfonic acid Salt. ¹ H
		NMR (DMSO-d6): δ 10.70 (s, 1H), 10.22 (s, 1H), 9.88 (s,
		1H), 8.19 (d, 1H, J= 5.3 Hz), 7.99 (d, 1H, J= 0.9 Hz), 7.72 (s,
		1H), 7.64 (d, 1H, J= 8.5 Hz), 7.46 (d, 2H, J= 8.0 Hz), 7.34
		(dd, 1H, J= 2.3 and 8.5 Hz), 7.19 (dd, 1H, J= 2.3 and 8.5 Hz),
		7.12 (s, 1H), 7.10 (d, 2H, J= 8.0 Hz), 6.87 (d, 1H, J= 8.5 Hz),
		2.27 (s, 3H), 1.36 (s, 6H). LCMS: ret. time: 8.39 min.; purity:
		100%: MS (m/e): 420 (MH ⁺)